US Archives - Page 112 of 130 - European Medical Journal

New Two-Dose Method Strengthens HIV Vaccine Response

A study highlights a significant advancement in HIV vaccine development: a two-dose priming strategy that optimizes the body’s immune response by aligning vaccine delivery with the germinal center (GC) reaction.

Advanced Imaging Techniques to Transform Arthritis Diagnosis

Adoption of cutting-edge imaging technologies and innovative use of existing methods may revolutionize the diagnosis and treatment of inflammatory arthritis.

BRCA Testing in Male Patients Slipping Through the Net

Greater BRCA genetic testing among men has been highlighted as a critical need in a recently published review

HFSA Cancels Annual Scientific Meeting Due to Hurricane Helene

The Heart Failure Society of America (HFSA) has made the difficult decision to cancel its 2024 Annual Scientific Meeting and the Devices in Heart Failure Meeting, originally scheduled for September 27-30 in Atlanta, Georgia.

RSV Threatens 50% of Healthy Infants Under 1

A new study reveals that over half of healthy U.S. infants contract respiratory syncytial virus in their first year, with 44.1% developing lower respiratory tract infections.

Is Preoperative Radiotherapy the Key to Glioblastoma Survival?

Preoperative radiotherapy may significantly enhance survival rates for glioblastoma, a particularly aggressive brain cancer.

Childhood Obesity’s Unexpected Impact on Skin

A strong link between childhood obesity and the development of immune-mediated skin diseases has been highlighted in new research.

Cancer Misinformation Online: A Growing Threat for Doctors

One-third of popular social media articles about breast, colorectal, lung, and prostate cancer contained misleading or harmful information, according to a new study.

One-Third of Adults Hesitant to Vaccinate This Fall

A national survey highlights rising vaccine hesitancy this flu season, with 37% of adults planning to skip flu and COVID-19 vaccines despite CDC recommendations.

Higher Secukinumab Dose Fails to Improve Outcomes

New study found that increasing secukinumab dosage to 300 mg provides no significant benefit for ankylosing spondylitis patients who did not respond to 150 mg.